Summary of the Conference Call Company and Industry Involved - **Company**: Innovent Biologics (信达生物) - **Partner**: Eli Lilly (礼来制药) - **Industry**: Biopharmaceuticals, specifically focusing on oncology and immunology Core Points and Arguments - **Strategic Collaboration**: Innovent Biologics announced a strategic partnership with Eli Lilly to advance the global development of innovative drugs in oncology and immunology [1] - **Development Responsibilities**: Innovent will lead the projects from drug discovery to clinical proof of concept in China, specifically completing Phase II clinical trials [1] - **Global Rights**: Eli Lilly will obtain exclusive global development and commercialization rights outside Greater China, while Innovent retains all rights within Greater China [1] - **Financial Terms**: Innovent will receive an upfront payment of $350 million, with potential milestone payments totaling up to approximately $8.5 billion based on specific future achievements [1] - **Sales Revenue Sharing**: Innovent is entitled to a tiered sales revenue share from net sales outside Greater China for each product [2] Additional Important Insights - **Seventh Collaboration**: This marks the seventh collaboration between Innovent and Eli Lilly, indicating a strong ongoing relationship [3] - **Risk Mitigation**: The "China PoC + global development" model reduces Innovent's overseas development risks while leveraging Eli Lilly's global network to enhance efficiency [4] - **Strategic Significance**: The collaboration's financial components will strengthen Innovent's financial security, and the sales revenue sharing will provide long-term benefits from global market growth [5] - **Synergy with Existing Pipeline**: The focus on oncology and immunology aligns with Innovent's existing core pipeline, including products like IBI363 (PD1/IL2) and IBI343 (CLDN18.2 ADC), enhancing overall competitiveness [5] - **Potential Early-Stage Products**: Other early-stage clinical products with significant market potential include IBI324 (VEGF-A/Ang-2), IBI3001 (EGFR/B7H3 ADC), and IBI3002 (IL-4Rα/TSLP) [5]

Core Viewpoint - The company, Innovent Biologics (01801), has seen its stock price increase by over 5%, currently trading at HKD 90.1, following the announcement of a strategic partnership with Eli Lilly to advance global R&D in oncology and immunology [1] Group 1: Strategic Partnership - Innovent Biologics has entered into its seventh strategic collaboration with Eli Lilly, focusing on innovative drug development in oncology and immunology [1] - The agreement includes an upfront payment of USD 350 million, with potential milestone payments totaling up to approximately USD 8.5 billion based on various development, regulatory, and commercialization milestones [1] - The partnership will also allow Innovent to receive a share of sales from related products in markets outside Greater China, enhancing its revenue potential [1] Group 2: Financial Implications - The upfront payment of USD 350 million is expected to be received soon, which will effectively cover the company's future overseas clinical investments [1] - Haitong International believes that the upfront and milestone payments will strengthen Innovent's financial safety net, while the sales share will provide long-term benefits from global market growth [1] - Goldman Sachs considers the current stock price undervalued, given the high implied weighted average cost of capital (12%), and has assigned a "Buy" rating with a target price of HKD 102.85 [1] Group 3: Competitive Positioning - The collaboration focuses on oncology and immunology, which aligns with Innovent's existing core pipeline, including IBI363 (PD1/IL2) and IBI343 (CLDN18.2ADC), enhancing overall competitiveness [1]

Core Viewpoint - The recent strategic partnership between Innovent Biologics and Eli Lilly is expected to enhance Innovent's financial stability and competitive position in the oncology and immunology sectors, with significant upfront and milestone payments involved [1][2]. Group 1: Financial Impact - Innovent Biologics has secured an upfront payment of $350 million from Eli Lilly, which will be received shortly and is intended to cover future overseas clinical investments [1]. - The total potential milestone payments could reach approximately $8.5 billion, providing a substantial financial cushion for the company [1]. - The sales sharing arrangement for products outside Greater China is expected to yield long-term benefits as the global market grows [2]. Group 2: Strategic Focus - The collaboration will focus on innovative drug development in oncology and immunology, aligning with Innovent's existing core pipeline, including IBI363 (PD1/IL2) and IBI343 (CLDN18.2 ADC) [2]. - This partnership is anticipated to enhance Innovent's overall competitiveness in the market by leveraging synergies with its current product offerings [2]. Group 3: Market Perception - Haitong International views the upfront and milestone payments as a reinforcement of Innovent's financial safety net, while Goldman Sachs believes the current stock price is undervalued, assigning a "Buy" rating with a target price of HKD 102.85 [2].

Core Viewpoint - The strategic partnership between Innovent Biologics and Eli Lilly marks a significant milestone in the global development of innovative drugs in oncology and immunology, with a total payment of $8.85 billion (approximately RMB 613 billion) involved in the agreement [2][5]. Group 1: Partnership Details - Innovent Biologics will lead the research and development from drug discovery to the completion of Phase II clinical trials in China, while Eli Lilly will have exclusive rights for global development and commercialization outside Greater China [4][5]. - The agreement includes an upfront payment of $350 million and potential milestone payments of up to $8.5 billion [5][6]. Group 2: Historical Context - This is the seventh collaboration between Innovent Biologics and Eli Lilly, with their first partnership dating back to 2015, which was notable for being the first instance of a Chinese biopharmaceutical company transferring overseas rights of self-developed antibody drugs to a Fortune 500 pharmaceutical giant [6][8]. - Over the years, the collaborations have expanded to include multiple innovative drug candidates, with significant milestone payments associated with each agreement [6][7]. Group 3: Financial Performance - Innovent Biologics has invested over RMB 10 billion in R&D from 2021 to 2024, reflecting a strong commitment to innovation despite previous financial losses [3][9]. - The company reported a significant turnaround in its financial performance in the first half of 2025, achieving a net profit of RMB 834 million, marking its first true profitability [9][10]. Group 4: Market Recognition - The company's stock price has doubled in the past year, with a current market capitalization exceeding RMB 1 trillion, indicating strong investor confidence [3][10]. - Innovent Biologics has successfully launched 17 innovative drugs over the past 14 years, with 12 of them included in the national medical insurance catalog, showcasing its competitive strength in the market [8][9].

Core Viewpoint - Goldman Sachs released a report stating that Innovent Biologics (01801) announced a milestone payment with Eli Lilly (LLY.US) and a tiered royalty based on net sales outside of China, indicating a positive outlook for the company [2] Group 1: Company Performance - Goldman Sachs considers the current market's implied weighted average cost of capital (12%) to be high, suggesting that Innovent's current stock price is undervalued [2] - The target price for Innovent Biologics is set at HKD 102.85 based on risk-adjusted discounted cash flow [2] Group 2: Competitive Position - Innovent Biologics is expected to maintain its leading position in China's biotechnology sector due to a strong pipeline of novel molecules targeting next-generation immuno-oncology [2] - The company has received encouraging preliminary data for IBI363 (a PD-1/IL-2α bispecific antibody), which shows differentiated drug characteristics in immunotherapy/cold tumors [2] Group 3: Strategic Partnerships - Innovent's strong commercialization capabilities and deep collaboration with global partners, particularly Eli Lilly, are highlighted as key advantages [2]

Investment Rating - The report does not explicitly state the investment rating for Innovent Biologics Core Insights - Innovent Biologics has entered into its seventh global strategic collaboration with Eli Lilly, focusing on the development of innovative drugs in oncology and immunology, with a deal size that exceeds expectations [1][4] - Innovent will lead the R&D work from drug discovery to Proof of Concept (PoC) in China, while retaining all rights in Greater China, which signifies international recognition of its R&D capabilities [2][5] - The collaboration is expected to strengthen Innovent's financial position through an upfront payment of USD 350 million and potential milestone payments of up to approximately USD 8.5 billion [1][4][6] - The focus on oncology and immunology aligns with Innovent's existing core pipeline, enhancing its overall competitiveness [2][6] Summary by Sections Strategic Collaboration - Innovent and Eli Lilly's collaboration will leverage Innovent's mature antibody technology platform and efficient clinical capabilities, reducing overseas development risks while enhancing efficiency through Lilly's global network [2][5] - The collaboration allows Innovent to lead early-stage R&D and retain rights in Greater China, marking a significant step in the globalization of Chinese innovative biopharmaceutical companies [5][6] Financial Implications - The upfront and milestone payments from the collaboration will provide a financial safety net for Innovent, while sales royalties will enable long-term benefits from global market growth [6] - Management projects that Innovent will achieve revenue of CNY 20 billion by 2027, with five products expected to enter MRCT Phase III clinical stages by 2030 [8] Pipeline and Market Potential - Innovent's oncology pipeline is expected to maintain its core market position, with additional growth drivers from integrated pipelines such as Mazdutide, Tolecimab, and Tetumumab [8] - Three assets, including IBI363, IBI343, and IBI324, are set to advance to global multi-regional Phase III clinical stages, with a combined market potential estimated at USD 60 billion [8]

Core Viewpoint - The collaboration between Innovent Biologics and Eli Lilly marks the seventh partnership aimed at advancing innovative drugs in oncology and immunology, with Innovent leading the development and retaining rights in Greater China while Eli Lilly secures global rights outside this region [1][2]. Group 1: Financial Aspects - Innovent will receive an upfront payment of $350 million and potential milestone payments totaling up to $8.5 billion [1]. - Following the announcement, Innovent's stock price surged by 7.42%, closing at HKD 85.40 per share, with a market capitalization of HKD 148.2 billion [2]. Group 2: Strategic Importance - The collaboration is characterized as a pure incremental partnership, focusing on new targets and molecules outside Innovent's existing clinical pipeline [2]. - Innovent's management highlighted the recognition of its R&D capabilities globally and the long-standing relationship with Eli Lilly as key factors for this partnership [2]. Group 3: Historical Context - Previous collaborations between Innovent and Eli Lilly include the development of the PD-1 inhibitor, which became a cornerstone product for Innovent after its launch in 2018 [3]. - Innovent has also introduced the GLP-1 dual receptor agonist from Eli Lilly, which is set to launch in 2025, marking a significant addition to its product portfolio [3]. Group 4: Market Position and Future Plans - Innovent is seen as a leading player in the domestic innovative drug sector, having capitalized on significant targets like PD-1 and GLP-1, which are closely associated with Eli Lilly [2][3]. - The company aims to enter a new phase of dual-driven product lines and internationalization by 2025, with plans to establish a global R&D and commercialization platform [8][9]. - Innovent's goal includes having five pipelines enter global multi-center Phase III clinical trials by 2030, with a revenue target of CNY 20 billion by 2027 [9].

（来源：药研网） 2025年2月9日，据CDE官网公示，信达生物已递交其1类新药IBI115的临床试验（IND）申请。 | | | 日 | | | | | --- | --- | --- | --- | --- | --- | | CXSL2600186 | IBI115 | 治疗用 生物制 | 新药 | 信达生物制药（苏州）有限公司; | 2026-02- 09 | 据公开资料，IBI115 是一款DLL3/CD3双特异性抗体药物，通过同时连接 T 细胞（通过 CD3）和肿瘤细胞（通过 DLL3），激活 T 细胞识 别并杀伤肿瘤细胞。 | ) 新药情报库 | 产品 > 数据 √ | 资源 √ | 版本对比 | Q 搜索药物、靶点、适应症、机构 ... | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | IBI115 | | | | | | | | | 概要 研发状态 | 临床结果 转化医学 | 药物交易 | 核心专利 | 临床分析 | 批准 | 生物类似药 | 特殊审评 | | 概要 | | | | | | | | | 基本信息 | | | ...

Core Insights - The collaboration between Innovent Biologics and Eli Lilly is valued at over $8.8 billion, marking a significant milestone in the pharmaceutical industry [1][2] - Innovent will receive an upfront payment of $350 million and has the potential to earn up to approximately $8.5 billion in milestone payments related to research, regulatory, and commercialization achievements [1][2] - This partnership represents a shift from traditional licensing agreements to a more integrated model involving deep collaboration on technology platforms and research systems [1][2] Group 1 - Innovent will lead the research and development from drug discovery to clinical concept validation in China, while Eli Lilly will have exclusive global development and commercialization rights outside Greater China [3][4] - The collaboration aims to combine Innovent's efficient drug discovery capabilities with Eli Lilly's extensive global reach, creating a synergistic innovation ecosystem [3][4] - The specific number of projects involved in this collaboration has not been disclosed, but it is indicated to be fewer than similar recent partnerships [3][4] Group 2 - Previous collaborations between Chinese pharmaceutical companies and multinational firms have involved a larger number of projects, such as the partnership between CSPC and AstraZeneca, which included eight projects [4] - Innovent's CEO noted that the success of such technology platform collaborations depends on the uniqueness and validation of the platform technology, as well as the contributions to intellectual property from both parties [4] - This marks the seventh collaboration between Innovent and Eli Lilly, indicating a strong existing relationship and mutual understanding [4][5] Group 3 - The trend of multinational companies shifting early-stage research work to China reflects their recognition of the research efficiency and capabilities of Chinese pharmaceutical firms [5] - Innovent achieved product revenues of 11.9 billion yuan in 2025, marking its first time surpassing 10 billion yuan, with a target of reaching 20 billion yuan by 2027 [5]

Group 1 - The Hang Seng Index closed up 1.8% at 27,027.16 points, driven by gains in drug manufacturer Innovent Biologics and toy manufacturer Pop Mart [1] - Innovent Biologics led the gains, closing up 7.4% after announcing a potential agreement with Eli Lilly that could bring up to $8.5 billion in milestone payments [1] - Citigroup analysts noted that this partnership could aid in the global expansion of the Chinese pharmaceutical company [1] Group 2 - Pop Mart closed up 5.8%, following comments from its CEO that the flagship Labubu dolls are expected to exceed sales of 10 million units by 2025 [1] - Other notable gainers included Zijin Mining, which rose by 5.6%, and Ping An Insurance, which increased by 4.9% [1]